Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06178939 | Effects of Cognitive Intervention Therapy on Postoperative Delirium | not yet recruiting | N/A | 60 | Yonsei UniversityOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05689619 | SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)(SILMET) | recruiting | N/A | 70 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06168032 | COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research | recruiting | N/A | 1,224 | Peking Union Medical College HospitalOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01475500 | Nashville Early Diagnosis Lung Cancer Project | active not recruiting | — | 480 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03066297 | Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer(OREX-IA) | active not recruiting | — | 1,018 | Samsung Medical CenterOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04379739 | Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 89 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05258448 | COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)(COLA) | recruiting | — | 100 | Odense University HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06052098 | Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer | recruiting | N/A | 110 | Hangzhou Broncus Medical Co., Ltd.INDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06142058 | RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC | recruiting | — | 44 | Xueqin YangOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06142617 | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | not yet recruiting | Phase 2 | 37 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06127329 | Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC | not yet recruiting | N/A | 70 | Gang WuOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06117644 | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | not yet recruiting | — | 30 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Nov 7, 2023 | clinicaltrials |
| NCT04790253 | PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)(PRIMALung) | recruiting | N/A | 600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Nov 3, 2023 | clinicaltrials |
| NCT06115447 | Polypropylene vs Polyglactin in Suturing of the Lung | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Nov 3, 2023 | clinicaltrials |
| NCT06116019 | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)(ART-02) | recruiting | — | 649 | Charite University, Berlin, GermanyOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06102161 | Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) | not yet recruiting | Phase 3 | 286 | Fudan UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05997719 | Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC | recruiting | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05550961 | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch | recruiting | — | 1,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05600569 | Registry of the Spanish Society of Thoracic Surgery(ReSECT) | recruiting | — | 30,000 | Sociedad Española de Cirugía TorácicaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT05988697 | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | not yet recruiting | — | 36 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05241028 | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05724004 | Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)(A-SAB) | recruiting | N/A | 70 | Karolinska University HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06067776 | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | not yet recruiting | Phase 1 | 36 | Jonathan RiessOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT05502913 | Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer | recruiting | Phase 2 | 80 | Soroka University Medical CenterOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT04631770 | Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC | recruiting | N/A | 1,362 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06056115 | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | recruiting | N/A | 20 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | recruiting | Phase 3 | 570 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05732974 | A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse(MIRACLE) | recruiting | — | 60 | University Hospital, ToulouseOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043973 | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance | recruiting | Phase 3 | 98 | Qianfoshan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04728724 | Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03742687 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC | recruiting | N/A | 151 | Danish Lung Cancer GroupOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05841472 | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | CrystalGenomics, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05998993 | Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)(CULTRO) | not yet recruiting | N/A | 35 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT06001151 | Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative(ACHELOUS) | recruiting | Phase 2 | 49 | Qian ChuOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05990127 | A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 642 | AkesoINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 21, 2023source: clinicaltrials